EPCAM and cholangiocarcinoma: Julich-Haertel et al. [50] observed increased levels of AnnexinV + EpCAM + ASGPR1 + EVs in patients with primary liver tumors (HCC or CCA) compared to cirrhotic patients without malignancy.